Filing Flows › Comparisons › PALI vs HUMA
Palisade Bio vs Humacyte: PALI and HUMA compared
Palisade Bio is the larger company: $500K of revenue in its latest quarter (Q2 2026) against $406K for Humacyte (Q2 2026).
Where the money goes: PALI and HUMA
Palisade Bio (PALI) · Q2 2026
Palisade Bio, Q2 2026: revenue $500K, net loss $10.6M, operating cash flow −$7.6M. The chart follows the revenue to costs, profit and cash.
Humacyte (HUMA) · Q2 2026
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
| Palisade Bio (PALI) | Humacyte (HUMA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $500K | $406K |
| Revenue growth, Y/Y | — | +35% |
| Operating margin | n/m | n/m |
| Net earnings | −$10.6M | −$36.8M |
| Operating cash flow | −$7.6M | −$22.1M |
Questions
Which is bigger, Palisade Bio or Humacyte?
Palisade Bio is the larger company: $500K of revenue in its latest quarter (Q2 2026) against $406K for Humacyte (Q2 2026).
More: Palisade Bio earnings · how Palisade Bio makes money · Humacyte earnings · how Humacyte makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.